Table 5.

ORR and MRD based on prior treatment history

SubgroupORR*MRD-negative rate (10−5)
Patients in group, n % Patients in group, n %
All response evaluable8284 1136
Refractory to lenalidomide4879520
Lenalidomide exposed but not refractory3090450
Refractory to bortezomib2584268
Refractory to IMiD5377520
IMiD exposed but not refractory2997650
Refractory to PI and IMiD248320
Cytogenetic risk
 High§1369367
 Standard5290633
  • * Data are based on a computerized algorithm.

  • Of the 27 patients who achieved CR or better, 11 received MRD testing.

  • Biomarker risk-evaluable population.

  • § Includes patients who have del17p, t(14;16), t(4;14) or a combination of these by fluorescence in situ hybridization or karyotype.